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Abstract
Background: For patients with MS, medication switches increase the risk of disease reactivation.
Objective: Compare discontinuation rates due to treatment failure or side effects between teriflunomide
and dimethyl fumarate, and investigate clinical variables affecting discontinuation rates.
Methods: All patients who received teriflunomide or dimethyl fumarate at Haukeland University
Hospital from 2013 until 2018 were identified. Clinical and demographic variables were extracted
from the Norwegian MS Registry. Cause-specific Cox regression models estimated the rate of discon-
tinuation due to treatment failure or side effects.
Results: We included 354 patients treated with either dimethyl fumarate (n¼ 185) or teriflunomide
(n¼ 169). We found 38% lower risk of discontinuation because of treatment failure for patients using
dimethyl fumarate compared to teriflunomide (p< 0.05). In a treatment-naive subgroup (n¼ 183), we
found a 38% reduced risk of discontinuation for any reason among patients using dimethyl fumarate
(p< 0.05). There was no significant difference between treatment groups in discontinuation rate due to
side effects, although more patients reported side effects when treated with dimethyl fumarate.
Conclusion: Our findings suggests that dimethyl fumarate has a lower risk of discontinuation because of
treatment failure among both treatment-experienced and treatment-naive patients.
Keywords: Multiple sclerosis, real-world data, therapeutics, disease-modifying therapies, observational
study, predictors of treatment outcomes, teriflunomide, dimethyl fumarate
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Introduction
For people with multiple sclerosis (MS), changing
medication increases the risk of reactivating the
disease, and tailoring treatment to each patient is
therefore important.1 For more than a decade,
injectable interferon-beta and glatiramer acetate




MA, USA) and dimethyl fumarate (TecfideraV
R
,
Biogen, Cambridge, MA, USA) became available
as oral first-line disease-modifying treatments in
Norway in 2013, many people with MS switched
to these newer options since they offered no painful
injections and a different side effects profile
without the flu-like symptoms often experienced
with the interferons.
The effectiveness of dimethyl fumarate and teriflu-
nomide in terms of reducing the annualized relapse
rate and the rate of disability progression has been
considered similar.2–5 A recent study has also found
that oral DMTs have a lower risk of discontinuation
of treatment in comparison to injectable DMTs.6
Dimethyl fumarate and teriflunomide have not
been compared directly, but real-world studies com-
paring both efficacy and discontinuation rates have
been presented recently with mixed results.7–11
Variables associated with discontinuation have
rarely been evaluated in these studies.
We aim to compare real-world discontinuation rates
due to treatment failure or side effects between
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teriflunomide and dimethyl fumarate using data
from the Norwegian Multiple Sclerosis Registry
and Biobank. We also aim to investigate clinical
variables affecting discontinuation rates, in order to
help identify any patient subgroups that could reach
a more stable treatment situation from one of the two
first-line options.
Methods and materials
This is a population-based retrospective observation-
al cohort study of terifunomide and dimethyl fuma-
rate in the treatment of multiple sclerosis.
Study population
Eligible for the study were all MS patients, aged
18 years, diagnosed according to the 2005 or
2010 McDonald criteria12,13 who received a pre-
scription for either dimethyl fumarate or terifluno-
mide at Haukeland University Hospital between 1
May 2013 and 1 February 2018. Only patients that
had consented for recording in the Norwegian
Multiple Sclerosis Registry were included. We iden-
tified patients from hospital administrative data pro-
vided by the Department of Neurology. The
government funds the health care system in
Norway, and treatment is therefore available to all
legal residents of Norway. Data were retrieved from
the Norwegian Multiple Sclerosis Registry comple-
mented by hospital records, from 1 January 2018
until 1 July 2018.
Exclusion criteria included a diagnosis of primary
progressive MS, lack of consent in the Norwegian
Multiple Sclerosis Registry, migration out of
Haukeland University Hospital’s catchment area,
lack of follow-up data, and if the patient never ini-
tiated the prescribed therapy. If a patient was pre-
scribed both treatments in the follow-up period, only
the first treatment was included. Follow-up started at
the initiation of treatment with either teriflunomide
or dimethyl fumarate. Patients were censored at dis-
continuation or at the end of the follow-up period for
drug survival analysis. If treatment was paused
because of pregnancy and restarted after pregnancy
and breastfeeding, we subtracted the period of dis-
continuation from the total time in treatment. We did
not include relapses occurring during this period in
the analysis, since they were not considered to indi-
cate treatment failure for either treatment.
Data collection and outcomes
We extracted patient data from the Norwegian
Multiple Sclerosis Registry and validated the infor-
mation by reviewing the medical records for each
patient. We registered information on age, sex, MS
phenotype, date of onset symptoms, date of diagno-
sis, number of clinical relapses, number of magnetic
resonance imaging (MRI) lesions at treatment start,
complete history of disease-modifying therapy prior
to switching to teriflunomide or dimethyl fumarate,
Expanded Disability Status Scale score (EDSS),
dates of treatment start and discontinuation, and
reason for switching treatment both to and from
dimethyl fumarate or teriflunomide. We also regis-
tered clinical relapses and new T2 and/or T1-
gadolinium weighted lesions and included them in
the analysis if they occurred at least 3months after
the first dose of therapy. We defined clinical relapses
based on the decision of the treating neurologist at
the time of clinical evaluation. Progression of dis-
ability as measured by EDSS was defined as an
increase by 1.0 points from a baseline EDSS
score of 5.5, or a 0.5 point increase from a base-
line EDSS score of >5.5, when not recorded within
30 days after the onset of a relapse.14,15 Side effects
were registered based on the description by the treat-
ing neurologist, and side effects registered as occur-
ring after the treatment period ended were not
included.
The primary outcome of this study was discontinu-
ation of treatment because of either treatment failure
or side effects. Treatment failure was defined as new
clinical relapses, new MRI T2 and/or T1-gadolinium
weighted lesions and/or progression of EDSS score
as described above. The secondary outcome for this
study was discontinuation for any reason among
treatment-naive patients.
Statistical analysis
We compared baseline characteristics using the
Mann–Whitney U-test for the continuous variables
and Pearson’s chi-square or, if necessary, Fisher’s
Exact test for the categorical variables. We analyzed
the possible correlation between the continuous var-
iables by using Spearman’s rho. We analyzed the
correlations between each of the continuous varia-
bles and each of the dichotomous categorical varia-
bles by calculating point-biserial or biserial
correlation coefficients. We set the significance
level at a p-value of less than 0.05 for all analyses.
Time to discontinuation of treatment was evaluated
using cox proportional hazards models. First, the
proportionality assumption for each variable along
with Schoenfeld’s global tests were performed. We
also tested the models for outliers and influential
cases before completing the analyses. There was
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one case with missing data, this case was not includ-
ed in the survival analyses.
We used cause-specific Cox regression models, as
opposed to a general model, to calculate the hazard
ratios of discontinuation. This was done in order to
avoid overestimating the parameters and to enable
further exploration of how each covariate influence
the discontinuation risk.16 In the cause-specific
model, the hazard ratios for discontinuation are esti-
mated by censoring the patients experiencing a com-
peting event when it occurs. In this study,
discontinuation because of treatment failure or
side-effects were the two main competing risks,
since a negligible proportion of patients terminated
treatment for other reasons.
Time to discontinuation because of treatment failure
or side effects were modelled by including the cova-
riates sex, age (18–25/26–45/46–65/> 66), disease
duration from first reported symptom, number of
baseline T2 and T1-gadolinium weighted MRI lesions
( 9 vs> 9), EDSS score at baseline (1,5/2,0–3,5/
4,0–5,5/ 6,0), number of prior relapses, number of
prior DMT switches, type of treatment used last
(treatment naı̈ve/injectable treatments/high efficacy
treatments) and treatment group (teriflunomide¼ 0,
dimethyl fumarate¼ 1). Both final models were
selected based on known influential variables com-
bined with the Akaike information criterion (AIC).17
For the treatment-naı̈ve subgroup, we performed a
general Cox proportional hazard regression analysis
with a stepwise forward method, since the number of
patients included did not enable cause-specific anal-
ysis. Time to discontinuation of treatment was mod-
elled by including the covariates sex, age (18–45
vs.> 45), disease duration from first reported symp-
tom, EDSS ( 1,5 vs> 1,5), number of baseline T2
and T1-gadolinium weighted MRI lesions ( 9
vs> 9), number of prior relapses and treatment
group (teriflunomide¼ 0, dimethyl fumarate¼ 1).
The final model was selected based on known influ-
ential variables combined with the Akaike informa-
tion criterion (AIC).
All statistical analyses were performed using IBM
SPSS Statistics, version 24 and R studio, version
1.4.1106.
Standard protocol approvals, registrations and
patient consent
The Northern Norway Regional Committee for
Medical and Health Research Ethics approved this
study with reference number 2018/1024. All includ-
ed patients have given written, informed consent to
be part of the Norwegian Multiple Sclerosis
Registry. The study conforms with the World
Medical Association Declaration of Helsinki.
Data availability
Anonymized data are available from the Norwegian
Multiple Sclerosis Registry and Biobank on reason-
able request from any qualified investigator upon
approval from the Norwegian Regional Committee
for Medical and Health Research Ethics.
Results
We identified 410 eligible patients and excluded 56
for reasons shown in Figure 1. We therefore includ-
ed 354 patients, 185 treated with dimethyl fumarate
and 169 treated with teriflunomide. We excluded
one patient with partly missing data in the Cox
regression analyses. Patients diagnosed with
Figure 1. Inclusion flow chart.
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Table 1. Baseline demographic and clinical characteristics.
Dimethyl fumarate (n¼ 185) Teriflunomide (n¼ 169)
Whole cohort (N¼ 354) M (SD) n (%) M (SD) n (%) p
Age 40.0 (12.0) 47.0 (11.0) <0.005
Female sex 131 (70.8) 116 (68.6) 0.728
MS phenotype 0.007
RRMS 166 (89.7) 151 (89.3)
SPMS 5 (2.7) 14 (8.3)
Other 14 (7.6) 4 (2.4)
Disease duration (years) 8.2 (9.6) 10.0 (10.5) 0.139
Relapses 2a (2)b 2a (2)b 0.857
MRI lesions> 9 91 (49.2) 91 (53.8) 0.396
EDSS 0.007
<1.5 114 (61.6) 73 (43.5)
2.0–3.5 50 (27.0) 65 (38.7)
4.0–5.5 11 (5.9) 18 (10.7)
>6 10 (5.4) 12 (7.1)
Last DMT used 0.065
Treatment naı̈ve 85 (45.9) 98 (58.0)
Injectable 78 (42.2) 58 (34.3)
Other 22 (11.9) 13 (7.7)
Number of prior DMT switches 1a (2)b 0a (1)b 0.013
Reason for last DMT switch
Treatment failure 29 (15.7) 16 (9.5) 0.109
Side effects 30 (16.2) 21 (12.4) 0.364
Dimethyl fumarate (n¼ 85) Teriflunomide (n¼ 98)
Treatment naı̈ve cohort (N¼ 183) M (SD) n (%) M (SD) n (%) p
Age 36 (12) 46 (12) <0.005
Female sex 64 (75.3) 74 (72.4) 0.737
MS phenotype 0.538
RRMS 79 (92.9) 92 (93.9)
SPMS 2 (2.4) 4 (4.1)
Other 4 (4.7) 2 (2.0)
Disease duration (years) 3.78 (6.99) 6.85 (9.75) 0.028
Relapses 1a (1)b 2a (1)b 0.503
MRI lesions> 9 38 (44.7) 47 (48.0) 0.766
EDSS 0.024
<1.5 63 (74.1) 54 (55.7)
2.0–3.5 17 (20.0) 38 (39.2)
4.0–5.5 1 (1.2) 1 (1.0)
>6 4 (4.7) 4 (4.1)
Disease duration is defined as years from first symptom to treatment start. Under MS Phenotype, the “other” category includes radiologically
isolated syndrome (RIS), clinically isolated syndrome (CIS) and at baseline unknown phenotype. Significant differences (p< 0.05) between
dimethyl fumarate and teriflunomide patient groups are marked in bold typeface.
aMedian.
bInterquartile range (IQR).
DMT: disease modifying therapy; EDSS: expanded disability status scale; M: mean; MRI: magnetic resonance imaging; MS: multiple
sclerosis; RRMS: relapsing remitting multiple sclerosis; SD: standard deviation; SPMS: secondary progressive multiple sclerosis.
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radiologically isolated syndrome (n¼ 4) or clinically
isolated syndrome (n¼ 10) were included. Among
the included patients, eight paused therapy because
of pregnancy. We followed up teriflunomide users
for a mean duration of 108 (95–122) weeks and
dimethyl fumarate users for 116 (104–129) weeks.
The patients treated with teriflunomide were older
and had a higher EDSS score when starting treat-
ment than patients treated with dimethyl fumarate
(Table 1). The same differences were also found
among the treatment-naive patients. The treatment
groups had different proportions of treatment-naive
patients, dimethyl fumarate n¼ 85 (46%), terifluno-
mide n¼ 98 (58%).
Figure 2 shows a cause-specific Cox regression anal-
ysis with time to discontinuation because of treat-
ment failure (A) and side effects (B) adjusted for
sex, age, MRI lesions at baseline, EDSS score and
the number of prior relapses at baseline. Patients
who received dimethyl fumarate had a significantly
lower risk of discontinuation because of treatment
failure than patients who received teriflunomide
(adjusted HR 0.62, 95% CI 0.39–0.99) (Figure 2
(a), Table 2). Patients aged 25 years and younger
had a higher risk of treatment failure than older
patients (p¼ 0.001, Table 2).
There was no difference in the risk of discontinua-
tion due to side effects between the two groups (HR
0.71, 95% CI 0.47–1.07) (Figure 2(b), Table 2).
Men had a lower risk of discontinuation compared
to women (HR 0.59, 95% CI 0.37–0.94). Those with
previous use of any disease modifying treatment had
a lower risk of discontinuation due to side effects
compared to treatment naı̈ve patients (p¼ 0.039,
Table 2).
In a separate adjusted cox analysis of treatment
naı̈ve patients (dimethyl fumarate n¼ 85, terifluno-
mide n¼ 98), patients who received dimethyl fuma-
rate had a significantly lower risk of discontinuation,
due to treatment failure or side effects combined,
than those who received teriflunomide (adjusted
HR 0.62, 95% CI 0.41–0.93, p¼ 0.021), (Figure 3,
Table 3). No other variables significantly affected
the risk of discontinuation.
Table 4 shows that altogether 83.2% of patients
treated with dimethyl fumarate and 60.9% treated
with teriflunomide reported side effects
(v2¼ 22.071, df¼ 1, p< 0.005). Patients receiving
dimethyl fumarate most frequently reported flushing
(40.1%) and gastrointestinal tract problems such as
nausea, diarrhea and stomach pain (26.3%). Patients
receiving teriflunomide most frequently reported
gastrointestinal tract problems (24.5%) and hair
loss (12.0%). Two patients treated with dimethyl
fumarate experienced an immediate allergic reac-
tion, one of whom was hospitalized. One patient
using teriflunomide was admitted to hospital with
toxic hepatitis. No cases of progressive multifocal
leukoencephalopathy were reported in either group.
Discussion
Patients receiving dimethyl fumarate had a 38%
lower risk of discontinuation because of treatment
failure than patients using teriflunomide. There
was no difference between the two treatment
Figure 2. Variables affecting drug survival. Cause-specific Cox proportional hazards regression analysis showing
adjusted time to discontinuation of treatment because of treatment failure (a) or side-effects (b). Both were analyzed using
a stepwise-forward approach. The models were adjusted for age, sex, MS phenotype, number of previous clinical relapses,
number of MRI lesions at treatment start, number of previous disease-modifying treatment switches and expanded
disability status scale (EDSS) score at treatment start.
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groups in risk of discontinuation due to side effects.
A separate analysis of treatment naı̈ve patients
showed that dimethyl fumarate users had a 38%
lower risk of discontinuing treatment for any
reason (treatment failure or side effects) compared
to teriflunomide users.
The lower risk of discontinuation because of treat-
ment failure among dimethyl fumarate users sug-
gests that this therapy was more effective, as
shown by others.9–11 One study comparing dimethyl
fumarate to teriflunomide reported a significantly
lower annualized relapse rate during a 2-year
period.9 In a time-to-event study, a lower risk of
relapses after 38months was found for dimethyl
fumarate in comparison with teriflunomide.18 A
cumulative incidence of discontinuation because of
disease breakthrough of 22% for teriflunomide users
versus 11% for dimethyl fumarate users has also
recently been reported.10 The latter study also
found that patients using dimethyl fumarate had a
23% lower hazard of relapsing. This outcome was
Table 2. Variables affecting drug survival.
Crude HR (95% CI) Adjusted HR (95% CI) Discontinued (n)
Discontinuation due treatment failure in the whole cohort (N¼ 354)
Sex Female (–) (–) 56
Male 0.99 (0.63–1.57) 0.92 (0.58–1.48) 27
Age group 18–25 (–) (–) 11
26–45 0.38 (0.19–0.92)* 0.33 (0.62–0.68)** 43
46–65 0.26 (0.13–0.54)* 0.20 (0.09–0.43)** 27
>66 0.32 (0.07–1.43) 0.19 (0.04–0.91)** 2
MRI lesions 9 (–) (–) 35
>9 1.43 (0.93–2.21) 1.58 (0.99–2.51) 48
Relapses 1.05 (0.98–1.13) 1.07 (0.99–1.15) 83
Last DMT used Naı̈ve (–) (–) 45
Injectable 0.57 (0.36–0.92)* 0.60 (0.37–0.99) 29
High efficacy 1.12 (0.55–2.30) 0.87 (0.37–2.02) 9
Treatment group Teriflunomide (–) (–) 38
Dimethyl fumarate 0.77 (0.50–1.19) 0.62 (0.39–0.99)* 45
Discontinuation due to side effects in the whole cohort (N¼ 354)
Sex Female (–) (–) 83
Male 0.65 (0.41–1.01)* 0.59 (0.37–0.94)* 25
Age group 18–25 (–) (–) 7
26–45 0.93 (0.42–2.06) 0.78 (0.34–1.77) 51
46–65 1.01 (0.45–2.23) 0.89 (0.38–2.07) 48
>66 0.61 (0.13–2.93) 0.72 (0.14–3.64) 2
MRI lesions 9 (–) (–) 56
>9 0.93 (0.64–1.35) 0.87 (0.58–1.23) 52
Prior DMT switches 1.23 (1.08–1.41)* 1.48 (1.11–1.97)* 108
Relapses 1.05 (0.99–1.12) 0.96 (0.88–1.05) 108
Last DMT used Naı̈ve (–) (–) 50
Injectables 0.87 (0.58–1.33) 0.54 (0.30–0.97)* 40
High efficacy 2.16 (1.26–3.71) 0.84 (0.31–2.25) 18
Treatment group Teriflunomide (–) (–) 54
Dimethyl fumarate 0.78 (0.53–1.14) 0.71 (0.47–1.07) 54
Variables influencing the risk of treatment discontinuation because of treatment failure or side effects in the adjusted cause-specific cox
proportional hazards model. (–): reference category.
Bold typeface: significant at p< 0.05 level. *: significant at p< 0.05 level; **: significant at p< 0.01 level.
CI: confidence interval; DMT: disease modifying treatment; HR: hazard ratio; MRI: magnetic resonance imaging.
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further supported by a study reporting that the pro-
portion of patients with at least one new T2 lesion
after 2 years was lower among dimethyl fumarate
users than among teriflunomide users.11
Even though more patients experienced side effects
from dimethyl fumarate, we found no difference in
discontinuation rate because of side effects. This
suggests that patients experienced the side effects
caused by dimethyl fumarate as less burdensome
than those caused by teriflunomide. Other recent
studies supports that dimethyl fumarate and teriflu-
nomide do not differ in side effects as the reason for
discontinuing treatment.7–9 However, previous
research has also reported side effects as the main
reason for switching treatment.7,8 We found that pre-
vious use of other disease-modifying treatments
reduced the risk of discontinuing treatment because
of side effects. We propose that these patients pre-
viously had experienced challenging side effects
from injectable or other disease-modifying therapies,
and thus better tolerated the side effects caused by
the newer medications. The women in our study had
a higher risk of discontinuing treatment than men.
This could mean that the type of side effects fre-
quently experienced, such as hair loss and flushing,
might be more demanding for women than for men.
Among treatment naı̈ve patients, the risk of treat-
ment discontinuation due to treatment failure or
side effects combined, was lower when receiving
dimethyl fumarate than teriflunomide. We could
not perform cause-specific analysis because of the
relatively low number of included patients in this
subgroup. This may have resulted in overestimating
the parameters calculated, and the results should
therefore be interpreted with caution.16
Nevertheless, we found the analysis to be of interest
and the effect size large enough to include the
results.
We did not select the patients in this study based on
narrow inclusion criteria. Our results therefore
reflect a real-world experience and are thus
Figure 3. Drug survival among treatment-naive patients.
Cox proportional hazards regression analysis showing
adjusted time to discontinuation of treatment due to
treatment failure or side effects combined among treat-
ment naı̈ve patients. The analysis was done using a step-
wise-forward approach, adjusting for age, sex, number of
previous clinical relapses, number of MRI lesions at
treatment start and expanded disability status scale (EDSS)
score at treatment start.
Table 3. Variables affecting drug survival in the treatment naı̈ve subgroup.
Discontinuation in the treatment
naı̈ve subgroup (N¼ 183) Crude HR (95% CI) Adjusted HR (95% CI) Discontinued (n)
Sex Female (–) (–) 85
Male 0.73 (0.46–1.15) 0.71 (0.45–1.12) 24
Age 45 (–) (–) 72
>45 0.78 (0.52–1.16) 0.66 (0.43–1.00) 37
EDSS 1.5 (–) (–) 68
>1.5 1.20 (0.81–1.78) 1.24 (0.82–1.87) 40
Relapses 1.03 (0.92–1.16) – 109
Treatment group Teriflunomide (–) (–) 57
Dimethyl fumarate 0.67 (0.45–0.99) 0.62 (0.41–0.93)* 52
Variables influencing the risk of treatment discontinuation for any reason, including treatment failure or side effects,
among treatment naı̈ve patients in the adjusted cox proportional hazards model. (–): reference category.
Bold typeface: significant at p< 0.05 level. *: significant at p< 0.05 level. **: significant at p< 0.01 level.
CI: confidence interval; EDSS: expanded disability status scale; HR: hazard ratio.
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applicable to a broader population than the more
rigorously selected study populations in randomized
clinical trials. However, there may be some limita-
tions, since the groups were not comparable at treat-
ment initiation. Patients using dimethyl fumarate
were younger on average and had a lower EDSS
score than those receiving teriflunomide. These dif-
ferences in baseline characteristics were enhanced in
the treatment naı̈ve subgroup. The choice of treat-
ment also shifted at our department during the obser-
vation period of this study. At first, dimethyl
fumarate was the preferred medication, since the
pivotal clinical trials reported a slightly higher
effect on annualized relapse rate.2,5 Later, since
2015, administrative treatment guidelines recom-
mended teriflunomide as the first choice due to
costs, except for women of reproductive age, who
are recommended dimethyl fumarate and not teriflu-
nomide because of its known potential teratogenic
effects.19,20
The choice of statistical analysis reflects the fact that
the groups were not comparable at treatment initia-
tion. We decided to use Cox regression models since
one of our objectives was to explore how different
clinical and demographic variables influence the dis-
continuation risk. A limitation of the analysis might
be that we did not correct for propensity scores. Still,
there are a few communications reporting that the
Cox proportional hazards regression model might be
equally good for balancing treatment groups when
analyzing time-to-event data.21,22 The statistical
model is also limited because some known con-
founders, such as smoking and socioeconomic
status, were not taken into account, since they are
incompletely reported in hospital records and the
Norwegian Multiple Sclerosis Registry.
Since both teriflunomide and dimethyl fumarate are
considered first-line treatment options, a further
study of discontinuation and efficacy among
treatment-naive patients would help clinicians and
patients in choosing first-line MS treatment. A new
study should also include data on socioeconomic
status such as education and employment, which
could be a motivating factor for patients to decide
to continue treatment.19
Conclusion
Our findings suggest that dimethyl fumarate has a
lower risk of discontinuation because of treatment
failure among both treatment-experienced and
treatment-naive patients. Also, easily available clin-
ical and demographic variables influence the risk of
discontinuation.
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